|
Feb 16
|
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
|
|
Feb 13
|
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
|
|
Feb 12
|
Shareholders in Bristol-Myers Squibb (NYSE:BMY) have lost 7.2%, as stock drops 5.4% this past week
|
|
Feb 11
|
The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings.
|
|
Feb 10
|
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
|
|
Jan 3
|
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
|
|
Jan 2
|
Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years
|
|
Oct 3
|
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
|
|
Oct 3
|
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
|
|
Oct 1
|
Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
|
|
Sep 30
|
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
|
Sep 27
|
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
|
|
Sep 27
|
Dow Rises to Record; Chinese Indexes Post Best Week in Years
|
|
Sep 27
|
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
|
|
Sep 27
|
FDA approves new Bristol Myers Squibb schizophrenia drug
|
|
Sep 27
|
Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug
|
|
Aug 10
|
Bristol-Myers Squibb Company's (NYSE:BMY) recent 4.2% pullback adds to one-year year losses, institutional owners may take drastic measures
|
|
Aug 8
|
Big Pharma Cuts R&D, Sending Shudders Through Industry
|
|
Jul 29
|
Big Pharma Rallies and Moves Past Obesity
|
|
Jul 27
|
Why Wall Street is unfazed by Medicare drug pricing threat
|